|
medical sciences |
32 |
|
hepatocellular carcinoma |
30 |
|
chronic hepatitis b |
28 |
|
nafld |
27 |
|
gastroenterology |
26 |
|
hbv |
25 |
|
cirrhosis |
23 |
|
entecavir |
23 |
|
hbsag |
21 |
|
hepatitis b |
21 |
|
adult |
20 |
|
functional cure |
20 |
|
hepatitis b virus |
20 |
|
hepatitis b surface antigen |
19 |
|
liver fibrosis |
18 |
|
liver transplantation |
18 |
|
nucleoside analogues |
18 |
|
antiviral therapy |
17 |
|
humans |
17 |
|
aged |
16 |
|
female |
16 |
|
liver stiffness |
16 |
|
male |
16 |
|
middle aged |
16 |
|
colonoscopy |
15 |
|
antiviral |
14 |
|
cap |
14 |
|
flare |
14 |
|
hcc |
14 |
|
prognosis |
14 |
|
tenofovir |
14 |
|
hcv |
13 |
|
liver biopsy |
13 |
|
metabolic syndrome |
13 |
|
nash |
13 |
|
nucleos(t)ide analogue |
13 |
|
vcte |
13 |
|
artificial intelligence |
12 |
|
chronic viral hepatitis |
12 |
|
diabetes mellitus |
12 |
|
fibrosis |
12 |
|
seroclearance |
12 |
|
vaccination |
12 |
|
acute flare |
11 |
|
age |
11 |
|
alanine aminotransferase |
11 |
|
anti-hbs |
11 |
|
biomarkers |
11 |
|
body mass index |
11 |
|
chronic liver disease |
11 |
|
controlled attenuation parameter |
11 |
|
decompensation |
11 |
|
hepatitis b core-related antigen |
11 |
|
hepatitis c |
11 |
|
liver failure |
11 |
|
long covid |
11 |
|
mafld |
11 |
|
meld |
11 |
|
non-alcoholic fatty liver disease |
11 |
|
post-covid-19 syndrome |
11 |
|
sars-cov-2 infection |
11 |
|
virus replication |
11 |
|
adolescent |
10 |
|
aged, 80 and over |
10 |
|
biomarker |
10 |
|
chronic hepatitis b virus |
10 |
|
hbcrag |
10 |
|
hbv dna |
10 |
|
m2bpgi |
10 |
|
surface antigen |
10 |
|
adefovir |
9 |
|
alanine transaminase - blood |
9 |
|
antiviral treatment |
9 |
|
apoptosis |
9 |
|
elasticity imaging techniques |
9 |
|
epidemiology |
9 |
|
fatty liver disease |
9 |
|
finite |
9 |
|
hav |
9 |
|
hbeag |
9 |
|
hepatitis c virus |
9 |
|
hev |
9 |
|
immigration |
9 |
|
lamivudine |
9 |
|
liver cancer |
9 |
|
mutation |
9 |
|
natural history |
9 |
|
non-viral liver disease |
9 |
|
nucleoside analogue |
9 |
|
pre-s deletions |
9 |
|
sglt2 inhibitors |
9 |
|
tumorigenesis |
9 |
|
carrier state |
8 |
|
core protein allosteric modulator |
8 |
|
elasticity imaging techniques - methods |
8 |
|
endocrinology |
8 |
|
fatty liver |
8 |
|
hepatitis b core antigen |
8 |
|
hepatitis b, chronic - complications - diagnosis |
8 |
|
hepatitis b, chronic - pathology |
8 |
|
hla‐dp |
8 |
|
ifn‐γ pathway |
8 |
|
liver cirrhosis - complications - diagnosis |
8 |
|
liver cirrhosis - pathology - virology |
8 |
|
liver failure - pathology - virology |
8 |
|
models, biological |
8 |
|
mortality |
8 |
|
nephrotoxicity |
8 |
|
predictive value of tests |
8 |
|
reproducibility of results |
8 |
|
serology |
8 |
|
telbivudine |
8 |
|
transplantation |
8 |
|
tricuspid annuloplasty |
8 |
|
accuracy |
7 |
|
adenocarcinoma |
7 |
|
advanced cirrhosis |
7 |
|
alanine aminotransferase blood level |
7 |
|
alanine transaminase - metabolism |
7 |
|
alkaline phosphatase |
7 |
|
biliary |
7 |
|
carcinoma, hepatocellular - etiology |
7 |
|
carcinoma, hepatocellular - virology |
7 |
|
cholangiogram |
7 |
|
colon cancer |
7 |
|
colorectal cancer |
7 |
|
covalently closed circular dna |
7 |
|
covid-19 |
7 |
|
deep learning |
7 |
|
diagnostic test accuracy study |
7 |
|
disease progression |
7 |
|
disease severity |
7 |
|
dna, viral - analysis |
7 |
|
drug response |
7 |
|
elastography |
7 |
|
etv |
7 |
|
gastric cancer |
7 |
|
gastroenterology medical sciences |
7 |
|
genome sequencing |
7 |
|
genomic diversity |
7 |
|
glp1 receptor agonists |
7 |
|
hepatitis b e antigens - metabolism |
7 |
|
hepatitis b virus - physiology |
7 |
|
hepatitis b virus infection |
7 |
|
hepatitis b, chronic - complications |
7 |
|
hepatitis b, chronic - drug therapy - virology |
7 |
|
hepatitis b, chronic - enzymology - pathology |
7 |
|
hepatorenal syndrome |
7 |
|
hong kong genome project |
7 |
|
interval cancer |
7 |
|
itraq |
7 |
|
ketamine |
7 |
|
liver cirrhosis - enzymology - pathology |
7 |
|
liver cirrhosis - etiology |
7 |
|
liver neoplasms - virology |
7 |
|
long read genome sequencing |
7 |
|
magnetic resonance cholangiography |
7 |
|
metabolic |
7 |
|
metabolic dysfunction–associated steatohepatitis |
7 |
|
obesity |
7 |
|
pioglitazone |
7 |
|
population-based genome project |
7 |
|
precision medicine |
7 |
|
rare disease |
7 |
|
short read genome sequencing |
7 |
|
substance abuse |
7 |
|
surgery |
7 |
|
treatment outcome |
7 |
|
vaccine |
7 |
|
adverse outcome |
6 |
|
anti-bacterial agents - pharmacology |
6 |
|
anti-hbc |
6 |
|
antibody to hepatitis b surface antigen |
6 |
|
aspartate aminotransferase |
6 |
|
blood donors - statistics and numerical data |
6 |
|
carrier state - epidemiology - pathology |
6 |
|
cccdna |
6 |
|
cigarette smoking |
6 |
|
circular dna |
6 |
|
clarithromycin |
6 |
|
colon neoplasms |
6 |
|
computed tomography |
6 |
|
curative colectomy |
6 |
|
cure |
6 |
|
drug resistance, viral |
6 |
|
fibroscan |
6 |
|
follow up |
6 |
|
full-length genome sequencing |
6 |
|
genotype 1 |
6 |
|
genotype 6 |
6 |
|
gitr |
6 |
|
gram-positive bacterial infections - epidemiology - microbiology - mortality - physiopathology |
6 |
|
guanine - analogs and derivatives - therapeutic use |
6 |
|
helicobacter pylori |
6 |
|
hepacivirus - classification - genetics - pathogenicity |
6 |
|
hepatic surgery |
6 |
|
hepaticolenticular degeneration |
6 |
|
hepatitis b core‐related antigen |
6 |
|
hepatitis b e antigens - blood |
6 |
|
hepatitis b serum markers |
6 |
|
hepatitis b virus - drug effects |
6 |
|
hepatitis b(e) antigen |
6 |
|
hepatitis b, chronic - blood - drug therapy - virology |
6 |
|
hepatitis b, chronic - complications - drug therapy |
6 |
|
hepatitis b, chronic - epidemiology - pathology |
6 |
|
hepatitis c, chronic - complications - metabolism - virology |
6 |
|
hong kong - epidemiology |
6 |
|
host-pathogen interactions |
6 |
|
hs-hbsag |
6 |
|
immune exhaustion |
6 |
|
interleukin‐27 |
6 |
|
intrahepatic hbv dna |
6 |
|
kinetics |
6 |
|
lamivudine - adverse effects - therapeutic use |
6 |
|
lamivudine - pharmacology - therapeutic use |
6 |
|
levofloxacin |
6 |
|
liver - pathology |
6 |
|
liver neoplasms - etiology |
6 |
|
longitudinal |
6 |
|
mac-2 binding protein glycosylation isomer |
6 |
|
microbial sensitivity tests |
6 |
|
na therapy |
6 |
|
nucleotide analogue |
6 |
|
pd-1 |
6 |
|
platelet ratio index |
6 |
|
primary biliary cholangitis |
6 |
|
prospective studies |
6 |
|
quasispecies |
6 |
|
recurrence |
6 |
|
regulatory t cells |
6 |
|
response to therapy |
6 |
|
retrospective studies |
6 |
|
reverse transcriptase inhibitors - therapeutic use |
6 |
|
risk factors |
6 |
|
shewanella - classification - drug effects - isolation & purification - pathogenicity |
6 |
|
spontaneous hbeag seroconversion |
6 |
|
t regulatory cells |
6 |
|
tenofovir hbsag surface antigen nucleoside analogue nucleotide analogue tdf |
6 |
|
time factors |
6 |
|
transient elastography |
6 |
|
treatment |
6 |
|
ursodeoxycholic acid |
6 |
|
viral hepatitis |
6 |
|
virus dna |
6 |
|
wfa + -m2bp |
6 |
|
anaemia |
5 |
|
angiotensin-converting enzyme inhibitors |
5 |
|
antiviral agents - administration and dosage - therapeutic use |
5 |
|
antiviral agents - adverse effects - therapeutic use |
5 |
|
biliary tract diseases - chemically induced - diagnosis |
5 |
|
cancer incidence |
5 |
|
cancer risk |
5 |
|
carcinoma, hepatocellular - diagnosis - pathology |
5 |
|
carcinoma, hepatocellular - epidemiology - genetics - virology |
5 |
|
ceruloplasmin - metabolism |
5 |
|
china |
5 |
|
cholangiopancreatography, endoscopic retrograde |
5 |
|
cohort analysis |
5 |
|
colonic adenoma. |
5 |
|
colonic neoplasms |
5 |
|
colonic polyp |
5 |
|
comorbidity |
5 |
|
copper/urine |
5 |
|
core antigen |
5 |
|
core protein |
5 |
|
ct |
5 |
|
customized therapies |
5 |
|
deep sequencing |
5 |
|
deleterious mutations |
5 |
|
dna mutational analysis - methods |
5 |
|
dna, viral - blood |
5 |
|
dyslipidemia |
5 |
|
efficacy |
5 |
|
endocuff |
5 |
|
fibrosis regression |
5 |
|
freezing |
5 |
|
gene deletion |
5 |
|
gene silencing |
5 |
|
genotype |
5 |
|
guanine - administration and dosage - analogs and derivatives - therapeutic use |
5 |
|
gut microbiota |
5 |
|
hbeag seroconversion |
5 |
|
hbsag seroclearance |
5 |
|
hbv // chb |
5 |
|
hbx protein |
5 |
|
hepatitis b e antigen |
5 |
|
hepatitis b surface antigens - blood |
5 |
|
hepatitis b surface antigens - blood - chemistry |
5 |
|
hepatitis b surface antigens - genetics |
5 |
|
hepatitis b virus - chemistry - classification - genetics |
5 |
|
hepatitis b virus - classification - genetics |
5 |
|
hepatitis b virus - drug effects - genetics |
5 |
|
hepatitis b virus - genetics |
5 |
|
hepatitis b virus - genetics - immunology - isolation and purification |
5 |
|
hepatitis b virus - genetics - isolation and purification |
5 |
|
hepatitis b virus dna rebound |
5 |
|
hepatitis b virus replication |
5 |
|
hepatitis b, chronic - complications - genetics - virology |
5 |
|
hepatitis b, chronic - complications - mortality - pathology |
5 |
|
hepatitis b, chronic - drug therapy - enzymology - immunology |
5 |
|
hepatitis b, chronic - epidemiology - physiopathology - virology |
5 |
|
hepatolenticular degeneration - complications - diagnosis - drug therapy - genetics - metabolism |
5 |
|
herbal medicine |
5 |
|
immune response |
5 |
|
immunomodulator |
5 |
|
inflammatory bowel disease |
5 |
|
inhalant abuse - complications |
5 |
|
intrahepatic hepatitis b virus dna |
5 |
|
ketamine - administration and dosage - adverse effects |
5 |
|
lamivudine - administration & dosage - therapeutic use |
5 |
|
linearized hbsag |
5 |
|
liver cirrhosis |
5 |
|
liver histology |
5 |
|
liver neoplasms - epidemiology - genetics - virology |
5 |
|
liver steatosis |
5 |
|
medical sciences - oncology |
5 |
|
medical sciences - urology and nephrology |
5 |
|
mitosis |
5 |
|
noninvasive |
5 |
|
nsaid |
5 |
|
nucleocapsid |
5 |
|
nucleos/tide analogues |
5 |
|
obese mice |
5 |
|
occult hepatitis b infection |
5 |
|
post‐colonoscopy colorectal cancer |
5 |
|
prevention |
5 |
|
propensity score |
5 |
|
protein precursors - genetics |
5 |
|
protein stability |
5 |
|
quantitative |
5 |
|
renin |
5 |
|
resistance |
5 |
|
reverse transcriptase inhibitors - administration & dosage - therapeutic use |
5 |
|
ribavirin |
5 |
|
risk assessment |
5 |
|
s-loss |
5 |
|
single polynucleotide polymorphisms |
5 |
|
specimen handling - methods |
5 |
|
statins |
5 |
|
steatosis |
5 |
|
stopping |
5 |
|
survival analysis |
5 |
|
sustained virologic response |
5 |
|
targeted sequencing |
5 |
|
therapeutic vaccine |
5 |
|
transcription |
5 |
|
translation |
5 |
|
treatment guidelines |
5 |
|
type 2 |
5 |
|
urologic diseases - chemically induced |
5 |
|
viraemia |
5 |
|
viral dna integration |
5 |
|
viral load |
5 |
|
virology |
5 |
|
young adult |
5 |
|
13c-urea breath test |
4 |
|
adjuvant |
4 |
|
adverse effects |
4 |
|
ai |
4 |
|
alt |
4 |
|
amoxicillin - therapeutic use |
4 |
|
anti-bacterial agents - therapeutic use |
4 |
|
anti-hepatitis b core total antibodies |
4 |
|
antibiotic resistance genes |
4 |
|
antibiotics |
4 |
|
antisense oligonucleotide |
4 |
|
b cell depletion |
4 |
|
bacteroides |
4 |
|
bariatric surgery - mortality |
4 |
|
besifovir |
4 |
|
bile acid |
4 |
|
biliary atresia |
4 |
|
biocide resistance genes |
4 |
|
breast feeding |
4 |
|
cancer |
4 |
|
capsid inhibitor |
4 |
|
care cascade |
4 |
|
carnitine |
4 |
|
carvedilol |
4 |
|
case report |
4 |
|
chinese |
4 |
|
chronic |
4 |
|
chronic kidney disease |
4 |
|
clarithromycin - therapeutic use |
4 |
|
cpsh |
4 |
|
cytokines |
4 |
|
diabetes mellitus, type 2 - prevention & control |
4 |
|
dialysis |
4 |
|
direct acting antiviral |
4 |
|
dna methylation |
4 |
|
dna polymerase inhibitor |
4 |
|
drug interaction |
4 |
|
drug therapy, combination - methods |
4 |
|
empirical first-line eradication |
4 |
|
end stage renal disease |
4 |
|
entry inhibitor |
4 |
|
estrogen |
4 |
|
face mask |
4 |
|
fanconi syndrome |
4 |
|
fatty liver - surgery |
4 |
|
gastric balloon |
4 |
|
gastric bypass - statistics & numerical data |
4 |
|
gastroplasty - statistics & numerical data |
4 |
|
gender difference |
4 |
|
genome editing |
4 |
|
global elimination |
4 |
|
gut microbiome |
4 |
|
hand sanitizer |
4 |
|
harm reduction |
4 |
|
hbsag level |
4 |
|
hbv reactivation |
4 |
|
hbv rna |
4 |
|
hbv transcription |
4 |
|
helicobacter infections - drug therapy |
4 |
|
helicobacter pylori - drug effects |
4 |
|
helicobacter pylori - treatment |
4 |
|
hepatitis |
4 |
|
hepatitis b core protein |
4 |
|
hepatitis b e antigen (hbeag) |
4 |
|
hepatitis b virus (hbv) dna |
4 |
|
hepatitis b virus rna |
4 |
|
histone acetylation |
4 |
|
hong kong |
4 |
|
hq-hbsag |
4 |
|
hsct |
4 |
|
ibrutinib |
4 |
|
ici |
4 |
|
imaging |
4 |
|
inflammation |
4 |
|
integrated dna |
4 |
|
interleukin-1 receptor type 1 knockout mice |
4 |
|
interleukin-1β |
4 |
|
ip-10 |
4 |
|
kidney |
4 |
|
kidney failure, chronic - therapy |
4 |
|
kidney transplantation |
4 |
|
lactic acidosis |
4 |
|
linkage to care |
4 |
|
lirads |
4 |
|
liver |
4 |
|
liver and renal dysfunction |
4 |
|
liver transient elastography |
4 |
|
liver transplant |
4 |
|
long-term |
4 |
|
malnutrition - etiology |
4 |
|
mash |
4 |
|
masld |
4 |
|
microbiota |
4 |
|
microrna |
4 |
|
model for end-stage liver disease |
4 |
|
muscle toxicity |
4 |
|
myopathy |
4 |
|
nadolol |
4 |
|
neoadjuvant |
4 |
|
novel therapy |
4 |
|
nsbb |
4 |
|
nucleos(t)ide analogs |
4 |
|
nucleoside analog |
4 |
|
nucleoside/ nucleotide analogue |
4 |
|
nucleotide analog |
4 |
|
obesity - surgery |
4 |
|
occult hepatitis b |
4 |
|
ofloxacin - therapeutic use |
4 |
|
omeprazole - therapeutic use |
4 |
|
oral therapy |
4 |
|
osteomalacia |
4 |
|
outcome |
4 |
|
peripheral neuropathy |
4 |
|
peritoneal dialysis |
4 |
|
peritonitis |
4 |
|
pharmacokinetics |
4 |
|
point of care test |
4 |
|
polymerase inhibitor |
4 |
|
portal hypertension |
4 |
|
prevalence |
4 |
|
programmed cell death protein 1 |
4 |
|
propranolol |
4 |
|
protease inhibitor |
4 |
|
pwid |
4 |
|
real-life |
4 |
|
renal dialysis - adverse effects |
4 |
|
renal toxicity |
4 |
|
rituximab |
4 |
|
rna interfering gene silencer |
4 |
|
rnai |
4 |
|
safety |
4 |
|
sars-cov-2 |
4 |
|
superior mesenteric artery syndrome |
4 |
|
superior mesenteric artery syndrome - etiology - radiography - therapy |
4 |
|
systemic therapy |
4 |
|
teratogenecity |
4 |
|
thiopurine |
4 |
|
tki |
4 |
|
tlr7 agonist |
4 |
|
tricuspid regurgitation |
4 |
|
varices |
4 |
|
viral entry inhibitor |
4 |
|
viremia |
4 |
|
weight loss - physiology |
4 |
|
acute-on-chronic liver failure |
3 |
|
adenosine a3 receptor |
3 |
|
adverse effect |
3 |
|
albendazole |
3 |
|
antiviral agents - therapeutic use |
3 |
|
arc-520 |
3 |
|
carcinoma |
3 |
|
coronavac |
3 |
|
cost–utility analysis |
3 |
|
covid-19 vaccine |
3 |
|
cpams |
3 |
|
direct-acting antiviral agents |
3 |
|
elbasvir/grazoprevir |
3 |
|
end stage liver disease - etiology - therapy |
3 |
|
guidelines |
3 |
|
healthcare dataset |
3 |
|
hepacivirus - genetics |
3 |
|
hepatitis b virus dna |
3 |
|
hepatitis b, chronic - complications - virology |
3 |
|
hepatitis c virus (hcv) |
3 |
|
hepatitis c, chronic - drug therapy - genetics - virology |
3 |
|
hepato-cellular carcinoma |
3 |
|
hepatocellular |
3 |
|
immunocompromised |
3 |
|
immunomodulation |
3 |
|
incidence |
3 |
|
interferon-alfa |
3 |
|
interleukins - genetics - therapeutic use |
3 |
|
linkage-to-care |
3 |
|
liver failure, acute - etiology - therapy |
3 |
|
liver neoplasms |
3 |
|
liver-related mortality |
3 |
|
model of end-stage liver disease |
3 |
|
monitor |
3 |
|
myrcludex b |
3 |
|
nucleocapsids |
3 |
|
nucs |
3 |
|
pancytopenia |
3 |
|
polymorphism, single nucleotide |
3 |
|
primary care |
3 |
|
rectal cancer |
3 |
|
strongyloidiasis |
3 |
|
subviral particles |
3 |
|
survival |
3 |
|
testing |
3 |
|
treatment cessation |
3 |
|
ulcerative colitis |
3 |
|
vaccine immunogenicity |
3 |
|
2-cl-ib-meca |
2 |
|
asian |
2 |
|
atherosclerosis |
2 |
|
big data analytics |
2 |
|
big data management |
2 |
|
cardiovascular disease |
2 |
|
discontinuation |
2 |
|
fg-3019 |
2 |
|
flares |
2 |
|
genotypes |
2 |
|
hbsag loss |
2 |
|
helipsav |
2 |
|
infectious disease |
2 |
|
infectious disease surveillance |
2 |
|
interferon-λ |
2 |
|
liver imaging |
2 |
|
machine learning |
2 |
|
msrc |
2 |
|
nf-kappa b |
2 |
|
nonalcoholic fatty liver disease |
2 |
|
nonalcoholic steatohepatitis |
2 |
|
predictors |
2 |
|
proportional hazards models |
2 |
|
qnr family |
2 |
|
radiology |
2 |
|
rep 9ac |
2 |
|
rheumatoid arthritis (ra) |
2 |
|
roc curve |
2 |
|
scale-b |
2 |
|
sustained response |
2 |
|
tenofovir alafenamide |
2 |
|
tenofovir disoproxil fumarate |
2 |
|
5-羟色胺 |
1 |
|
5-羟色胺再摄取转运蛋白 |
1 |
|
alcohol |
1 |
|
alcoholic liver disease |
1 |
|
antibody to hepatitis b core antigen |
1 |
|
antibody to tumor necrosis factor |
1 |
|
antigen cd20 |
1 |
|
body-mass index |
1 |
|
bone mineral density |
1 |
|
bone safety |
1 |
|
cardiovascular disease risk |
1 |
|
chronic hepatitis b virus infection |
1 |
|
coffee |
1 |
|
diabetes |
1 |
|
framingham risk score |
1 |
|
hbx基因 |
1 |
|
hematopoietic stem cell transplantation |
1 |
|
hepatic steatosis |
1 |
|
intestinal epithelial cells |
1 |
|
ldl |
1 |
|
magnetic resonance imaging proton density fat fraction (mri-pdff) |
1 |
|
metabolic dysfunction-associated steatohepatitis |
1 |
|
noncontrast |
1 |
|
non‐alcoholic steatohepatitis |
1 |
|
nuclear factor-κb |
1 |
|
occult |
1 |
|
physical activity |
1 |
|
quantification |
1 |
|
renal safety |
1 |
|
resmetirom |
1 |
|
steatohepatitis |
1 |
|
thbxδ35 |
1 |
|
ultrasound-derived fat fraction (udff) |
1 |
|
viremia reduction |
1 |
|
依从性 |
1 |
|
受试者 |
1 |
|
多西环素/治疗应用 |
1 |
|
影响因素 |
1 |
|
慢病毒载体 |
1 |
|
溃疡性结肠炎 |
1 |
|
细胞增殖 |
1 |
|
肝细胞 |
1 |
|
肠嗜铬细胞 |
1 |
|
色氨酸羟化酶1 |
1 |
|
药物临床试验 |
1 |
|
螺杆菌,幽门/药物作用 |
1 |
|
螺杆菌感染/药物疗法 |
1 |
